Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1618-36-6 | MDL No. : | MFCD09264586 |
Formula : | C7H6ClN3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | NISJMYPRXDUYTF-UHFFFAOYSA-N |
M.W : | 167.60 | Pubchem ID : | 14809282 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.14 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 43.86 |
TPSA : | 41.57 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.91 cm/s |
Log Po/w (iLOGP) : | 1.64 |
Log Po/w (XLOGP3) : | 1.99 |
Log Po/w (WLOGP) : | 1.92 |
Log Po/w (MLOGP) : | 1.11 |
Log Po/w (SILICOS-IT) : | 2.62 |
Consensus Log Po/w : | 1.86 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.74 |
Solubility : | 0.306 mg/ml ; 0.00183 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.49 |
Solubility : | 0.543 mg/ml ; 0.00324 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.53 |
Solubility : | 0.049 mg/ml ; 0.000292 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.39 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
49.1% | Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 0.583333 h; Stage #2: at 20℃; |
PREPARATION 8; 4-Chloro-5-methyl-7H-pyrrolor2,3-dlpyrimidine <n="118"/>n-Butyllithium (4.08 ml, 6.52 mmol) was added dropwise to 5-bromo-4-chloro-7H- pyrrolo[2,3-d]pyrimidine (689mg, 2.96 mmol) in tetrahydrofuran (40ml) at -780C over a period of 5 minutes under nitrogen. The resulting suspension was stirred at -78 0C for 30 minutes. Methyl iodide (0.295 ml, 4.74 mmol) was added and the reaction was allowed to warm to ambient temperature. The reaction mixture was diluted with water (25 mL), and extracted with ethyl acetate (50 mL). The organic layer was washed with brine (25 mL) then dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 20 to 50percent EtOAc in isohexane. Pure fractions were evaporated to dryness to afford 4-chloro-5-methyl-7H- pyrrolo[2,3-d]pyrimidine (244 mg, 49.1 percent) as a white solid. IH NMR (400.13 MHz, DMSO-d6) δ 2.42 (3H, d), 7.43 (IH, d), 8.51 (IH, s), 12.22 (IH, s)MS nVe MH+ 168 |
49.1% | Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 0.583333 h; Stage #2: at -78 - 20℃; |
PREPARATION J <n="110"/>4-chloro-5-methyl-7H-pyrrolor2,3-dlpyrimidine; n-Butyllithium (4.08 ml, 6.52 mmol) was added dropwise to 5-bromo-4-chloro-7H- pyrrolo[2,3-d]pyrimidine (689mg, 2.96 mmol) in tetrahydrofuran (40ml) at -780C over a period of 5 minutes under nitrogen. The resulting suspension was stirred at -78 0C for 30 minutes. Methyl iodide (0.295 ml, 4.74 mmol) was added and the reaction was allowed to warm to ambient temperature. The reaction mixture was diluted with water (25 mL), and extracted with ethyl acetate (50 mL). The organic layer was washed with brine (25 mL) then dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 20 to 50percent EtOAc in isohexane. Pure fractions were evaporated to dryness to afford 4-chloro-5-methyl-7H- pyrrolo[2,3-d]pyrimidine (244 mg, 49.1 percent) as a white solid.IH NMR (400.13 MHz, DMSO-d6) δ 2.42 (3H, d), 7.43 (IH, d), 8.51 (IH, s), 12.22 (IH, s) MS m/e MH+ 168 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
83% | With N-chloro-succinimide In dichloromethane at 43℃; for 8 h; | A. Preparation of 4,5-dichloro-7H-pyrrolo[2,3-d]pyrimidine; Following the procedure in Pdulo, J. S.; Saxena, N. K.; Nassiri, M. R.; Turk, S. R.; Drach, J. C.; Townsend, L. B. J. Med. Chem. 31:2086 (1988), 4-chloro-5-methyl-7H-pyrrolo[2,3-d]pyrimidine (Example 1A, 20. g, 0.13 mol) was suspended in anhydrous dichloromethane (500 mL), followed by addition of N-chlorosuccinimide (20.8 g, 0.160 mol). The reaction mixture was refluxed at 43° C. for 8 hours. The reaction was cooled down, and the white solid was filtered, washed with dichloromethane (300 mL), and dried to give 4,5-dichloro-7H-pyrrolo[2,3-d]pyrimidine (20 g, 83percent) |
[ 24391-41-1 ]
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Similarity: 0.89
[ 35808-68-5 ]
4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.85
[ 115093-90-8 ]
4,5-Dichloro-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.85
[ 71149-52-5 ]
4-Chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.83
[ 123148-78-7 ]
4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.80
[ 24391-41-1 ]
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Similarity: 0.89
[ 35808-68-5 ]
4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.85
[ 115093-90-8 ]
4,5-Dichloro-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.85
[ 71149-52-5 ]
4-Chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.83
[ 123148-78-7 ]
4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
Similarity: 0.80